A 104-Week, Flexible-Dose, Open-Label, Multicenter, Extension Study to Evaluate the Long-Term Safety and Effectiveness of Lurasidone in Pediatric Subjects With Schizophrenia and Subjects With Irritability Associated With Autistic Disorder

Trial Profile

A 104-Week, Flexible-Dose, Open-Label, Multicenter, Extension Study to Evaluate the Long-Term Safety and Effectiveness of Lurasidone in Pediatric Subjects With Schizophrenia and Subjects With Irritability Associated With Autistic Disorder

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 30 Oct 2017

At a glance

  • Drugs Lurasidone (Primary)
  • Indications Autistic disorder; Schizophrenia
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Sunovion Pharmaceuticals
  • Most Recent Events

    • 27 Oct 2017 Interim results (n =155) presented in a Sunovion Pharmaceuticals media release.
    • 05 Jul 2017 Planned number of patients changed from 574 to 702.
    • 03 Mar 2017 Planned End Date changed from 1 Jul 2018 to 1 Oct 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top